CASI (STOCKS)
CASI Pharmaceuticals, Inc. Ordinary Shares
$0.850000
+0.109600 (+14.80%)
Prev close: $0.740400
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- David A. Cory
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $13.18M
- Employees
- 233
- P/E (TTM)
- -0.27
- P/B (TTM)
- -0.51
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.67 | $-0.41 | -0.2620 | -64.22% |
|
Jun 2025 (Q2)
|
$-0.86 | $-0.48 | -0.3806 | -79.39% |
|
Mar 2025 (Q1)
|
$-0.69 | $-0.62 | -0.0678 | -10.90% |
|
Sep 2024 (Q3)
|
$-0.55 | $-0.63 | +0.0824 | +13.03% |
Financial Statements
| Revenues | $37.01M |
| Benefits Costs and Expenses | $63.32M |
| Cost Of Revenue | $15.36M |
| Costs And Expenses | $54.41M |
| Gross Profit | $21.65M |
| Operating Expenses | $54.41M |
| Depreciation and Amortization | $642.00K |
| Other Operating Expenses | $53.77M |
| Operating Income/Loss | -$32.76M |
| Income/Loss From Continuing Operations After Tax | -$26.69M |
| Income/Loss From Continuing Operations Before Tax | -$26.31M |
| Interest Income/Expense After Provision For Losses | $161.00K |
| Interest Income/Expense Operating, Net | $161.00K |
| Net Income/Loss | -$26.31M |
| Net Income/Loss Attributable To Noncontrolling Interest | $384.00K |
| Net Income/Loss Attributable To Parent | -$27.08M |
| Net Income/Loss Attributable To Redeemable Noncontrolling Interest | -$1.42M |
| Net Income/Loss Available To Common Stockholders, Basic | -$27.08M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | $1.03 |
| Diluted Earnings Per Share | $1.03 |
| Basic Average Shares | 287,787,685 |
| Diluted Average Shares | 287,787,685 |
| Assets | $127.91M |
| Current Assets | $55.61M |
| Inventory | $5.77M |
| Other Current Assets | $49.84M |
| Noncurrent Assets | $72.29M |
| Fixed Assets | $13.87M |
| Intangible Assets | $10.05M |
| Other Non-current Assets | $48.38M |
| Liabilities | $44.69M |
| Current Liabilities | $29.75M |
| Accounts Payable | $3.10M |
| Other Current Liabilities | $26.65M |
| Noncurrent Liabilities | $14.94M |
| Redeemable Noncontrolling Interest | $21.50M |
| Redeemable Noncontrolling Interest, Common | $21.50M |
| Equity | $61.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $61.71M |
| Temporary Equity | $21.50M |
| Liabilities And Equity | $127.91M |
| Net Cash Flow From Operating Activities | -$27.89M |
| Net Cash Flow From Operating Activities, Continuing | -$27.89M |
| Net Cash Flow From Investing Activities | $8.46M |
| Net Cash Flow From Investing Activities, Continuing | $8.46M |
| Net Cash Flow From Financing Activities | $5.96M |
| Net Cash Flow From Financing Activities, Continuing | $5.96M |
| Net Cash Flow | -$13.94M |
| Net Cash Flow, Continuing | -$13.47M |
| Comprehensive Income/Loss | -$31.60M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$3.59M |
| Comprehensive Income/Loss Attributable To Parent | -$28.01M |
| Other Comprehensive Income/Loss | -$2.00M |